The disclosure is directed in non-limiting embodiments to compounds, compositions, and methods of treating conditions and diseases associated with activation of the gonadotropin GnRH receptor (GnRHR), particularly those involving GnRHR activating autoantibodies (GnRHR AAbs). In one non-limiting embodiment, the disease is Polycystic Ovary Syndrome (PCOS). The therapeutic compounds in at least certain embodiments include peptides which at least partially comprise D-amino acids, such as retro-inverso D-amino acid (RID) peptides, which are able to bind with high affinity to GnRHR AAbs.

The disclosure is directed in non-limiting embodiments to compounds, compositions, and methods of treating conditions and diseases associated with activation of the gonadotropin GnRH receptor (GnRHR), particularly those involving GnRHR activating autoantibodies (GnRHR AAbs). In one non-limiting embodiment, the disease is Polycystic Ovary Syndrome (PCOS). The therapeutic compounds in at least certain embodiments include peptides which at least partially comprise D-amino acids, such as retro-inverso D-amino acid (RID) peptides, which are able to bind with high affinity to GnRHR AAbs.

The present invention concerns the use of a combination consisting of D-aspartic and L-aspartic acids or L-aspartic acid used alone to stimulate the procreative activity in the man by increment of spermatozoon number and motility.

The present invention refers to field of assisted reproductive technologies, in particular to a sperm storage media, and describes mTOR enhancers, preferably the mTOR activator MHY 1485, as supplement for storage media, said supplemented media increasing sperm motility and viability during short-term room temperature storage, while sustaining the metabolic rates, without changing its fertilization potential (capacitation) and DNA integrity.

The present disclosure relates to compositions and methods for ablating epithelial cells, in particular to methods for ablating Sertoli cells in testis, and methods related thereto. In particular, the present disclosure relates to methods for ablating Sertoli and other cells in the testis using benzalkonium chloride, to methods for rescuing endogenous spermatogenesis in a subject suffering from Sertoli cell dysfunction, to methods of reconstructing spermatogenesis, to methods of treating infertility, and to methods for the selective depletion of epithelial cells in a tissue and for the treatment of diseases or disorders associated with damaged epithelial cells.

The present disclosure relates to compositions and methods for ablating epithelial cells, in particular to methods for ablating Sertoli cells in testis, and methods related thereto. In particular, the present disclosure relates to methods for ablating Sertoli and other cells in the testis using benzalkonium chloride, to methods for rescuing endogenous spermatogenesis in a subject suffering from Sertoli cell dysfunction, to methods of reconstructing spermatogenesis, to methods of treating infertility, and to methods for the selective depletion of epithelial cells in a tissue and for the treatment of diseases or disorders associated with damaged epithelial cells.

The invention relates to a sprayable liquid solution for the transdermal delivery of testosterone comprising testosterone, a penetration enhancer, and a film forming excipient, and to methods of treatment using this composition.

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof.

The present disclosure relates to novel pharmaceutical composition for the administration of testosterone or testosterone derivatives using an aqueous nasal administration. The present disclosure also provides methods of treatment of diseases and disorders associated with fear and anxiety, a decrease in libido, or hypogonadism.